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The pathogenesis of pulmonary arterial hyper-
tension (PAH) is complex and poorly under-
stood; however, pulmonary arterial endothelial 
cell (EC) injury is considered to be a critical 
early mechanism in the initiation and progres-
sion of disease (Budhiraja et al., 2004; Voelkel 
and Cool, 2004; Song et al., 2008). The dis-
tal pulmonary arteriolar bed normally lacks 
muscularization at the level of the intraacinar 
arteriole, which essentially consists of an EC 
tube with limited matrix support (Tuder et al., 
2001) exposed directly to the environment 
through inspired air. Therefore, we have hy-
pothesized that these uniquely fragile precapil-
lary structures may be particularly susceptible 
to damage upon exposure to environmental 
stress, especially in the context of genetic pre-
disposition, and that EC apoptosis contributes 
to the functional and structural abnormalities of 
the pulmonary microvasculature characteristic 
of this disease.
Tie2 belongs to the family of endothelial-
selective receptor tyrosine kinases and is essential 
for both embryonic and postnatal angiogenesis 
(Dumont et al., 1994; Sato et al., 1995; Suri   
et al., 1996; Ward and Dumont, 2002). Angio-
poietin-1  (Ang1)  and  Ang2  are  the  principle 
Tie2 ligands. Ang1 is a Tie2 agonist and func-
tions as a homeostatic factor in the postnatal vas-
culature, protecting against EC inflammation 
and apoptosis mainly through activation of the 
Akt pathway (Papapetropoulos et al., 2000). In 
contrast, Ang2 was first identified as an endoge-
nous antagonist to Tie2 (Maisonpierre et al., 
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The role of the angiopoietin-1 (Ang1)–Tie2 pathway in the pathogenesis of pulmonary 
arterial hypertension (PAH) is controversial. Although Ang1 is well known to prevent endo-
thelial activation and injury in systemic vascular beds, this pathway has been suggested to 
mediate pulmonary vascular remodeling in PAH. Therefore, we used transgenic models to 
determine the effect of increased or decreased Tie2 activity on the development of PAH. 
We now report modest spontaneous elevation in right ventricular systolic pressure in Tie2-
deficient mice (Tie2+/) compared with wild-type (WT) littermate controls, which was 
exacerbated upon chronic exposure to the clinically relevant PAH triggers, serotonin (5-HT) 
or interleukin-6 (IL-6). Moreover, overexpression of Ang1 in transgenic mice had no dele-
terious effect on pulmonary hemodynamics and, if anything, blunted the response to 5-HT. 
Exposure to 5-HT or IL-6 also decreased lung Ang1 expression, further reducing Tie2 
activity and inducing pulmonary apoptosis in the Tie2+/ group only. Similarly, cultured 
pulmonary artery endothelial cells subjected to Tie2 silencing demonstrated increased 
susceptibility to apoptosis after 5-HT treatment. Finally, treatment of Tie2-deficient mice 
with Z-VAD, a pan-caspase inhibitor, prevented the pulmonary hypertensive response to  
5-HT. Thus, these findings firmly establish that endothelial survival signaling via the Ang1–
Tie2 pathway is protective in PAH.
© 2009 Kugathasan et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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and 0.05, respectively; Fig. 1, A and B). Interestingly, basal 
protein levels of Ang1 in the lung were slightly increased in 
Tie2+/ compared with WT mice (P < 0.01), whereas Ang2 
levels were reduced (P < 0.01), resulting in a more than 
twofold increase in the ratio of lung Ang1 to Ang2 levels (P < 
0.05; Fig. 1 C). Under basal conditions, there was a modest 
but significant difference in RVSP between WT and Tie2+/ 
mice (P < 0.05), with 13% of the Tie2+/ mice demonstrat-
ing a RVSP measurement >37 mmHg (two standard devia-
tions above mean RVSP of WT mice; 2, P < 0.05 compared 
with WT mice; Fig. 2 A); however, no significant change 
in baseline systemic systolic blood pressure (SBP; Fig. 2 B) 
or heart rate (unpublished data) was observed. A marked 
reduction in microvascular perfusion in the lungs of Tie2+/   
compared with WT mice was revealed after fluorescent   
microangiography (Fig. 2 C). Furthermore, this perfusion 
abnormality was more pronounced in mice with higher RVSPs. 
To further characterize their susceptibility to PAH, WT and 
Tie2+/ mice were subjected to 1 wk of hypoxic exposure 
(8–10% O2). Chronic hypoxia resulted in a significant in-
crease in RVSP and right ventricle (RV) hypertrophy (P < 
0.05 and 0.01, respectively, compared with normoxic con-
trols), but there was no significant difference between the 
hypoxic WT and Tie2+/ mice observed (Fig. S1).
Effect of 5-HT or IL-6 on RVSP and RV hypertrophy
To determine the effect of well-known pulmonary hyperten-
sive stimuli, RVSP (Fig. 3 A) and RV hypertrophy (Fig. 3 B) 
were assessed in WT and Tie2+/ mice after 1 wk of 5-HT 
infusion and 1 or 2 wk of IL-6 delivery. Treatment with 
5-HT had no significant effect on RVSP in WT mice, although 
there was a trend (P < 0.1) toward an increase. However,   
5-HT–treated Tie2-deficient mice exhibited a substantial in-
crease in RVSP compared with their respective saline-treated 
controls (40 ± 4 vs. 25 ± 1 mmHg; P < 0.01). This increase was 
also significantly greater than that seen in WT mice exposed 
to 5-HT (27 ± 2 mmHg; P < 0.05). Although no significant 
effect on RVSP was observed in any group after 1 wk of IL-6 
delivery, 2 wk of exposure to IL-6 induced a significant ele-
vation in RVSP in Tie2+/ mice compared with IL-6–treated 
WT mice (31 ± 3 vs. 22 ± 1 mmHg; P < 0.05). A trend (P < 
0.1) toward an increase in RVSP was also observed in Tie2+/ 
mice compared with their saline-treated controls. No signifi-
cant change in RV hypertrophy was observed in either the 
WT or Tie2+/ mice during the short period of treatment 
with 5-HT. However, a significant increase in RV hypertro-
phy was observed in Tie2+/ compared with WT mice after 
2 wk of exposure to IL-6 (P < 0.05).
Effect of 5-HT or IL-6 on Ang1 level and Tie2 activity
Western blot analysis was performed on lung homogenates 
from WT and Tie2+/ mice to determine whether treatment 
with 5-HT or IL-6 altered endogenous Ang1 levels (Fig. 4, 
A and B). After 1 wk of exposure to 5-HT or IL-6, Ang1 
levels were significantly and similarly decreased in WT and 
Tie2+/ mice compared with their respective saline-treated 
1997) but is now recognized to have context-dependent ago-
nistic properties, and has been reported to activate the Tie2 
receptor at high concentration (Kim et al., 2000) or during 
prolonged incubation (Teichert-Kuliszewska et al., 2001).
Despite considerable evidence supporting a protective ac-
tion for the Ang1–Tie2 pathway in systemic blood vessels 
(Chen and Stinnett, 2008; Lai et al., 2008; Lee et al., 2008), the 
role of this system in the pulmonary microvasculature, particu-
larly in PAH, remains highly controversial. Thistlethwaite et al. 
reported remarkable increases in Ang1 expression and Tie2 ac-
tivity in the lungs of PAH patients compared with control lung 
samples, in which both were nearly undetectable (Thistlethwaite 
et al., 2001; Du et al., 2003). However, other groups have found 
high basal levels of Ang1 expression and Tie2 activity in 
the  normal human lung (Kugathasan et al., 2005; Eddahibi   
et al., 2006); indeed, the lung has been reported to exhibit the 
highest levels of Ang1–Tie2 expression and activity of all organs 
(Wong et al., 1997; Witzenbichler et al., 1998). Nonetheless, 
the Thistlethwaite group has also reported that overexpression 
of Ang1 by means of transfection with adenoviral (Sullivan   
et al., 2003) or adeno-associated viral vectors (Chu et al., 2004) 
produced PAH in rats. Again, these findings are in conflict with 
other reports demonstrating that nonviral Ang1 gene transfer 
reduced right ventricular systolic pressure (RVSP) and vascular 
remodeling in both the monocrotaline (Zhao et al., 2003) and 
chronic hypoxia (Kugathasan et al., 2005) models of PAH, even 
improving survival in the former. These discrepancies may be 
related to confounding influences of viral vectors that were used 
for transfection, because these may have proinflammatory ef-
fects, or surgical manipulation, in particular the clamping of 
delicate pulmonary veins that was performed to enhance pul-
monary gene transfer (Sullivan et al., 2003; Chu et al., 2004).
Therefore, in the present study we relied on transgenic ap-
proaches to study the effects of both loss or gain of function of 
the Ang1–Tie2 pathway on pulmonary hemodynamics and 
remodeling. We now report that Tie2 heterozygous deficient 
mice showed mild spontaneous increases in RVSP and an 
exaggerated pulmonary hypertensive response to chronic ex-
posure to serotonin (5-HT) or IL-6. This was associated with de-
creased lung Ang1 levels and Tie2 receptor activation, and 
increased peripheral lung apoptosis in Tie2-deficient mice only. 
Moreover, the inhibition of apoptosis with a pan-caspase   
inhibitor, Z-VAD, prevented PAH in response to 5-HT in 
Tie2+/ animals, whereas overexpression of Ang1 using a con-
ditional transgenic model did not result in PAH and, if any-
thing, blunted the pulmonary hypertensive response to 5-HT 
exposure. Therefore, the evidence from these transgenic mod-
els supports the view that the Ang1–Tie2 pathway acts to pro-
tect against the development of PAH, largely by preventing 
apoptosis and early lung microvascular loss.
RESULTS
Phenotypic characterization of WT and Tie2+/ mice
Western blot analysis of lung Tie2 and endothelial NO syn-
thase (eNOS) protein revealed a reduction of 50% in ex-
pression levels in Tie2+/ compared with WT mice (P < 0.01 JEM VOL. 206, September 28, 2009 
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(A and B) (P < 0.05). Because baseline levels of eNOS were 
significantly down-regulated in Tie2+/ mice (Fig. 1 B), we 
examined eNOS protein expression in WT and Tie2+/ mice 
after 5-HT infusion (Fig. S3). Interestingly, although there 
was no significant reduction in lung eNOS protein levels after 
5-HT exposure, a trend toward a decrease (P < 0.1) was ob-
served in the Tie2-deficient group.
Cell-death analysis
No terminal deoxynucleotidyl transferase–mediated dUTP 
nick-end labeling (TUNEL) staining or propidium iodide 
(PI) uptake was detected in saline-treated WT or Tie2+/ 
mice (not depicted). In contrast, substantial TUNEL positiv-
ity was seen after 1 wk of exposure to 5-HT in Tie2-deficient 
but not in WT mice (7 vs. 0%; P < 0.01; Fig. 6 A). This in-
crease in apoptosis was confirmed by in vivo perfusion of the 
pulmonary circulation with PI, which only stains the nuclei 
of nonviable cells. Again, only Tie2+/ mice exposed to 5-HT 
demonstrated an increased uptake of PI (Fig. S4). Similarly, 
after 1 wk of exposure to IL-6, only Tie2-deficient mice 
control groups (P < 0.05). To further establish the association 
between 5-HT and Ang1, human pulmonary artery smooth 
muscle cells (SMCs) were exposed for 24 h to 5-HT (108–
105 M) or a combination of equal concentrations of IL-6 
and a soluble IL-6R (sIL-6R; 10, 50, and 100 ng/ml), be-
cause past studies (Modur et al., 1997; Ammit et al., 2007) 
have demonstrated that the membrane-bound receptor may 
not be expressed in SMCs under in vitro conditions and that 
the soluble receptor is required to allow for IL-6 trans-signal-
ing (Fig. S2). Ang1 secretion, as determined by ELISA per-
formed on conditioned media, was reduced to 60% in 
response to 5-HT or IL-6/sIL-6R (P < 0.01; Fig. 4, C and D). 
To investigate the implications of these observations on in 
vivo Tie2 activity, Western blot analysis of phosphorylated 
Tie2 was performed on lung homogenates (Fig. 5, A and B). 
Although in WT mice no change in Tie2 receptor activation 
was observed after 5-HT infusion or IL-6 injections, Tie2+/ 
mice displayed a significant decrease in lung Tie2 receptor 
activation compared with their saline-treated groups, in par-
allel to the decreases in Ang1 levels demonstrated in Fig. 4   
Figure 1.  Characterization of lung protein expression in WT and Tie2+/ mice under basal conditions. (A and B) Decreased lung Tie2 (A; n = 5 
mice per group) and eNOS protein levels (B; n = 3 mice per group) in Tie2+/ compared with WT mice. (C) Increased lung Ang1 and decreased lung Ang2 
protein levels, and increased ratio of lung Ang1 to Ang2 protein levels in Tie2+/ compared with WT mice (n = 5 mice per group). Results in A and C are 
from two independent experiments, and results in B are from one experiment. Data are presented as means ± SEM. *, P < 0.05; **, P < 0.01 versus WT.2224 TIE2 DEFICIENCY AND PULMONARY HYPERTENSION | Kugathasan et al.
lular matrix composition between WT and Tie2+/ mice af-
ter exposure to 5-HT or IL-6 (Fig. S5).
Lack of PAH in Ang1 transgenic mice
Protein expression of the human Ang1 transgene was de-
tected in the mouse plasma of binary transgenic (BT) mice 
after induction by doxycycline withdrawal (Fig. S6). To de-
fine the effects of Ang1 overexpression on the development 
of PAH, RVSP and RV hypertrophy were determined in 
11–12-wk-old Ang1 BT mice and non-BT (NBT) littermate 
controls that had been released from doxycycline suppression 
at 3 wk of age, and then received infusions of 5-HT or saline 
for 1 wk before end-study assessments. As presented in Fig. 9 A, 
there were no significant differences in RVSP between Ang1 
BT and NBT mice receiving either saline or 5-HT infusions; 
if anything, RVSP tended to be reduced in BT mice, but this 
was not significant. As well, no differences in RV hypertro-
phy were observed between the groups after 1 wk of saline or 
5-HT treatment (Fig. 9 B).
Effect of caspase inhibition
To further establish the role of EC apoptosis in the exagger-
ated pulmonary hypertensive response to 5-HT in vivo, we 
treated WT or Tie2-deficient animals with a pan-caspase in-
hibitor, Z-VAD. In WT mice, Z-VAD had no effect, whereas 
in Tie2+/ mice, this treatment completely prevented the   
demonstrated TUNEL staining within peripheral regions of 
the lung (6%), whereas no staining was seen in WT mice 
(P < 0.01; Fig. 6 B).
Effect of reduced Tie2 expression and 5-HT  
on pulmonary artery EC survival
To further define the effect of decreased Tie2 receptor expres-
sion and signaling on EC survival in response to 5-HT, Tie2 
was knocked down in human pulmonary artery ECs using 
specific silencing siRNA. Transfection with specific siRNA 
reduced Tie2 protein expression by 50% by Western analy-
sis, compared with control, scrambled siRNA–treated ECs 
(P < 0.01; Fig. 7 A). Furthermore, Tie2 silencing significantly 
enhanced EC apoptosis induced by 10 µM 5-HT cultured in 
low serum (0.2% fetal bovine serum) compared with cells 
treated with scrambled siRNA (P < 0.01; Fig. 7 B).
Effect of 5-HT or IL-6 on pulmonary vascular remodeling
Exposure to 5-HT for 1 wk did not result in any differences 
in the muscularization of pulmonary vessels <50 µm in diam-
eter in either WT or Tie2-deficient mice (unpublished data). 
However, Tie2+/ mice exposed to 2 wk of IL-6 demon-
strated a significant increase in muscularization compared with 
saline-treated Tie2+/ and IL-6-treated WT mice (P < 0.01 
for both comparisons; Fig. 8, A and B). Preliminary studies 
demonstrated no overt phenotypic differences in extracel-
Figure 2.  Hemodynamic analysis and pulmonary fluorescent microangiography in WT and Tie2+/ mice under basal conditions. (A) Elevation 
in baseline RVSP measurements in Tie2+/ (n = 55) compared with WT (n = 60) mice. (B) No significant difference in systemic SBP between WT and Tie2+/ 
mice was observed (n = 5 mice per group). (C) Fluorescent microangiography (whole top right lung lobe) illustrating decreased microcirculatory perfusion 
in baseline Tie2+/ compared with WT mice; perfusion is further reduced in mice with higher RVSP measurement (n = 5 mice per group). Results in A are 
from 10 independent experiments, each with similar proportions of WT and Tie2+/ mice; results in B are from 2 independent experiments; and represen-
tative photomicrographs in C are from three independent experiments. Data are presented as means ± SEM. *, P < 0.05 versus WT. Bars, 0.25 cm.JEM VOL. 206, September 28, 2009 
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The distal pulmonary arteriolar bed is unique in that it 
consists of little more than an endothelial tube with scant 
matrix and few, if any, supporting mural cells. Thus, the ECs 
of the precapillary arterioles may be particularly vulnerable to 
injurious stimuli, and thereby more dependent on survival 
signaling, such as that afforded by Ang1 and vascular endo-
thelial growth factor, to maintain lung vascular homeostasis. 
This is consistent with previous observations that inhibiting 
vascular endothelial growth factor signaling can potentiate 
experimental PAH (Taraseviciene-Stewart et al., 2001), 
whereas overexpression of angiogenic factors can be protec-
tive (Janssens et al., 1996; Campbell et al., 2001; Zhao et al., 
2003; Kugathasan et al., 2005; Zhao et al., 2005). Moreover, 
we hypothesize that the functional consequences of even low 
levels of EC apoptosis may be particularly important for this 
region, because there is a finite possibility that this could dis-
rupt the functional continuity between the arteriolar and 
capillary circulations, effectively excluding an “arteriolar-capillary 
unit” from the efficient “low pressure” pulmonary circulation. 
If this occurs repeatedly over time throughout the lung micro-
vasculature, this would result in progressive increases in pul-
monary vascular resistance.
Tie2 is an endothelial-selective receptor tyrosine kinase 
that is essential for vascular growth and remodeling. A null 
mutation of Tie2 results in embryonic lethality at E9.5–12.5 
with marked vascular abnormalities, including reduced vascular 
exaggerated increase in RVSP induced by 5-HT (P < 0.01; 
Fig. 10 A). In addition, no significant change in RV hyper-
trophy was present at 1 wk (Fig. 10 B). Furthermore, no 
TUNEL-positive cells were detected in the lungs of Tie2+/ 
mice receiving both 5-HT and Z-VAD (not depicted).
DISCUSSION
In this study, we examined whether alterations in Tie2 ac-
tivity would protect or predispose to the development of 
PAH using loss- and gain-of-function transgenic models. 
Ang1 overexpression by itself did not induce PAH, and 
Tie2 haploinsufficiency resulted in spontaneous increases in 
RVSP in a small proportion of mice under basal conditions. 
Moreover chronic treatment of Tie2-deficient mice with 
5-HT or IL-6 unmasked significant elevation in pulmonary 
arterial pressures compared with WT animals. These inter-
ventions also reduced lung Ang1 levels and Tie2 activity, 
and induced EC apoptosis both in vivo and in vitro, but 
only in the context of Tie2 deficiency. As well, inhibition of 
apoptosis with Z-VAD completely prevented the pulmo-
nary hypertensive response to 5-HT in Tie2+/ mice. These 
data strongly suggest that the Ang1–Tie2 pathway protects 
against PAH, in large part by promoting EC survival under 
conditions of serotonergic or inflammatory stress, both of 
which have been strongly implicated in the pathogenesis of 
this disease.
Figure 3.  Effect of 5-HT or IL-6 on RVSP and RV hypertrophy. (A) Increased RVSP in Tie2+/ mice exposed to 5 nmol/h 5-HT for 1 wk compared 
with WT mice and compared with saline-treated Tie2+/ mice (n = 12–15 mice per group). Increased RVSP in Tie2+/ mice exposed to 200 ng/kg/d IL-6 for 
2 wk compared with WT mice (n = 9–13 mice per group). (B) No change in RV hypertrophy, assessed by evaluating the mass ratio of the RV to the left 
ventricle plus septum (LV+S), in WT or Tie2+/ mice exposed to 5 nmol/h 5-HT for 1 wk compared with saline-treated groups (n = 12–15 mice per group). 
Increased RV hypertrophy in Tie2+/ mice exposed to IL-6 for 2 wk compared with WT mice (n = 9–13 mice per group). Results are from three indepen-
dent experiments. Data are presented as means ± SEM. *, P < 0.05; **, P < 0.01 as indicated.2226 TIE2 DEFICIENCY AND PULMONARY HYPERTENSION | Kugathasan et al.
contribute to EC dysfunction and loss in this model. Thus, 
we hypothesized that Tie2 deficiency would exaggerate pul-
monary vascular response to relevant environmental triggers 
of PAH by predisposing to EC apoptosis and microvascular 
degeneration.
Despite the evidence supporting a key role for the Ang1–
Tie2 pathway in maintaining vascular homeostasis, it has pre-
viously been suggested that Ang1 may be causally related to 
the development of PAH (Thistlethwaite et al., 2001; Du   
et al., 2003). This was based on the observation that Ang1 
complexity, increased EC apoptosis, and an absence in mural 
cell recruitment (Davis et al., 1996). Furthermore, Ang1 is 
highly expressed by SMCs and pericytes in the postnatal vas-
culature, and promotes vascular stabilization and maintenance 
of EC quiescence (Maisonpierre et al., 1997). Of interest, the 
lung exhibits some of the highest levels of basal Ang1 expres-
sion of any organ in the body (Wong et al., 1997). In addi-
tion, Tie2-deficient mice exhibited a marked down-regulation 
of lung eNOS protein levels, and any reduction in the release 
of the vascular protective and EC survival factor, NO, could 
Figure 4.  Effect of 5-HT or IL-6 on Ang1 protein levels in vivo and in vitro. (A) Decreased lung Ang1 protein levels in WT and Tie2+/ mice after 
exposure to 5-HT (A; n = 5 mice per group) or IL-6 (B; n = 5 mice per group) for 1 wk. (C and D) Decreased Ang1 protein secretion measured by ELISA in 
pulmonary artery SMCs serum starved overnight and stimulated with 108–105 M 5-HT (C; n = 4 per group) or equal concentrations of a combination of 
IL-6 and sIL-6R (10, 50, and 100 ng/ml; D; n = 4 per group) for 24 h. Results in A and B are from two independent experiments; results in C and D are 
from four independent experiments. Data are presented as means ± SEM. *, P < 0.05; **, P < 0.01 versus saline (in vivo) or control (in vitro).JEM VOL. 206, September 28, 2009 
ARTICLE
2227
storage before analysis. Indeed, we have found that the levels 
of Ang1 mRNA and protein fall off precipitously even after 
a 15-min delay in the processing of lung samples (unpub-
lished data).
The Thistlethwaite group also demonstrated that increas-
ing Tie2 activity by Ang1 gene transfer resulted in medial 
hyperplasia of pulmonary arterioles, vascular obstruction, and 
PAH (Sullivan et al., 2003; Chu et al., 2004), whereas in-
hibition of this signaling pathway via gene transfer of the 
extracellular domain of Tie2 (soluble Tie2) was protective 
(Kido et al., 2005). However, patients with an activating 
mutation of Tie2 show no evidence of PAH but rather de-
velop large venous malformations, which exhibit either nor-
mal muscularization or vascular walls that are totally devoid 
of medial SMCs (Vikkula et al., 1996). Moreover, using a 
conditional transgenic Ang1 overexpression strategy to avoid 
the confounding effects of viral vectors, we found no evi-
dence of an increase in RVSP or RV remodeling even 9 wk 
after induction of Ang1 gene expression. Furthermore, BT 
mice harboring both the tetracycline trans-activator and the 
Ang1 transgenes showed no evidence of enhanced suscepti-
bility to PAH in response to serotonergic stress, and if any-
thing, this was blunted. These findings are consistent with 
previous studies in which nonviral Ang1 gene transfer pre-
vented PAH in rats in both the monocrotaline and hypoxia 
models (Zhao et al., 2003; Kugathasan et al., 2005).
The reasons for the marked discrepancies between our 
findings and those of the Thistlethwaite group are not clear; 
however, this may relate to differences in the experimental 
approaches. For example, their studies used viral vectors for 
gene transfer that can induce inflammation. It is also possible 
that differences in the overall magnitude of transgene expres-
sion (i.e., “dose”) or spatial distribution may have contributed 
to these divergent results, and that higher levels of local Ang1 
expression within the lung microvasculature could induce 
nonphysiological  effects,  such  as  increased  muscularization 
and arterial remodeling. Finally, surgical manipulation such as 
the clamping of the pulmonary veins that was used to en-
hance the levels of transgene expression in the lung in these 
studies (Sullivan et al., 2003; Kido et al., 2005) could have 
damaged these delicate venous structures. It is well established 
in the electrophysiology literature that injury to pulmonary 
veins is an important cause of pulmonary hypertension   
(Robbins et al., 1998; Tsao and Chen, 2002; Yang et al., 2007). 
In our study, the use of a conditional, targeted transgenic model 
may have avoided some of these confounding effects.
Of note, we found an increase in basal levels of Ang1 in 
Tie2+/ compared with WT mice, which was associated with 
decreased Ang2 expression. This resulted in a marked in-
crease in the ratio of the Tie2 agonist over the antagonist, 
which could serve to enhance activation of the remaining re-
ceptors, possibly in compensation for the effects of Tie2 hap-
loinsufficiency. Although overt PAH was not evident in most 
Tie2-deficient mice, abnormalities in distal microcirculatory 
perfusion were revealed by fluorescent microangiography, 
which were similar to those observed in a dominant-negative 
was robustly expressed in lung samples from associated PAH 
patients, and was strongly correlated with increases in pul-
monary vascular resistance, whereas Ang1 protein and Tie2 
activity were nearly undetectable in control human lung samples 
(Thistlethwaite et al., 2001; Du et al., 2003). However, these 
findings are in conflict with other reports showing that Ang1 
is highly expressed in normal human and rodent lungs (Wong 
et al., 1997; Witzenbichler et al., 1998; Abdulmalek et al., 
2001; Kugathasan et al., 2005), and an up-regulation of Ang1 
in PAH has not been confirmed by other groups (Kugathasan 
et al., 2005; Dewachter et al., 2006). It is possible that the 
near-complete absence of Ang1 mRNA and protein expres-
sion in control lung samples in the initial Thistlethwaite re-
port (Thistlethwaite et al., 2001) was related to their use of 
lobectomy samples from routine surgeries, which are often 
subjected to variability in processing speed and duration to 
Figure 5.  Effect of 5-HT or IL-6 on lung Tie2 activity. (A and B) 
Decreased activation of Tie2, assessed by normalizing levels of phos-
phorylated Tie2 to total Tie2, in Tie2+/ mice treated with 5-HT (A; n = 4 
mice per group) or IL-6 (B; n = 4 mice per group) for 1 wk compared 
with saline-treated Tie2+/ mice. No change in Tie2 activation was ob-
served in WT mice. Results in A and B are from two independent ex-
periments. Data are presented as means ± SEM. *, P < 0.05 versus 
respective saline Tie2+/ mice.2228 TIE2 DEFICIENCY AND PULMONARY HYPERTENSION | Kugathasan et al.
the “second-hit” hypothesis for the pathogenesis of this disease, 
in which the response to an environmental or endogenous 
trigger is enhanced by the presence of a sensitizing genetic 
abnormality (Newman et al., 2004; Song et al., 2005; Long 
et al., 2006; Song et al., 2008). In a manner analogous to the 
present findings, exposure to serotonergic (Long et al., 2006) 
or inflammatory stressors (Song et al., 2005) also produced an 
enhanced pulmonary hypertensive response in BMPR2+/ 
mice. Interestingly, as in Tie2-deficient mice, exposure to 
BMPR2  transgenic  mouse  model  (West  et  al.,  2008)  and 
consistent with subthreshold effects on vascular structure and 
function. In the present study, exposure to 5-HT or IL-6 
alone did not induce a significant elevation in RVSP in WT 
mice; similarly, Tie2 deficiency by itself resulted in only a 
minor effect. However, the combination of these genetic and 
environmental influences appeared to have “synergistic” ef-
fects resulting in the initiation of pulmonary apoptosis and 
the development of significant PAH. This is consistent with 
Figure 6.  Effect of 5-HT or IL-6 on lung apoptosis. (A and B) Increased TUNEL staining in Tie2+/ compared with WT mice after exposure to 5-HT 
(A; n = 4 mice per group) or IL-6 (B; n = 4 mice per group) for 1 wk. TUNEL staining on 5-µm-thick paraffin-embedded lung sections from (a) WT and  
(c) Tie2+/ mice. Merged image of TUNEL and nuclear stainings (TO-PRO-3) of (b) WT and (d) Tie2+/ mice (arrows indicate TUNEL-positive cells). (e) Magnified 
view of TUNEL-positive cells (arrows) and (f) the percentage of TUNEL-positive cells. Results in A and B are from two independent experiments. Data are 
presented as means ± SEM. **, P < 0.01 versus WT. Bars: (a–d) 50 µm; (d, inset) 25 µm; (e) 12.5 µm.JEM VOL. 206, September 28, 2009 
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Similarly, 5-HT has been strongly implicated in PAH, with 
idiopathic PAH patients demonstrating elevated circulating 
levels of 5-HT (Hervé et al., 1995). In experimental mod-
els, administration of dexfenfluramine (Dempsie et al., 2008), 
a 5-HTT substrate that also elevates extracellular levels of 
5-HT (Rothman et al., 1999), has been shown to induce PAH 
in mice. In addition, several genetic and pharmacological 
models to either increase or decrease the activity of 5-HT 
receptors or the transporter have further highlighted the role   
of 5-HT in PAH (MacLean et al., 1996; Morecroft et al., 
1999; Eddahibi et al., 2000; Keegan et al., 2001; Hironaka 
et al., 2003; Marcos et al., 2003; MacLean et al., 2004; 
Guignabert et al., 2005; Long et al., 2006; Morecroft et al., 
2007), in part through its direct stimulatory effects on pul-
monary arterial SMCs. However, the effects of 5-HT on EC 
growth and survival have not been as extensively studied. 
Lee et al. (1994) have reported that although 5-HT stimu-
lated DNA synthesis in bovine pulmonary artery SMCs, this 
effect was not seen in pulmonary artery ECs. Similarly, we 
found no effects of 5-HT on EC growth and survival under 
basal conditions, but substantial EC apoptosis was demon-
strated in response to 5-HT after siRNA-induced Tie2 gene 
silencing. Thus, 5-HT may have differential effects on pul-
monary vascular cells; although in SMCs it promotes pro-
liferation, in ECs it may induce injury and apoptosis.
This is analogous to the effects of BMPR2 deficiency or 
gene silencing, which also results in dysregulated SMC growth 
but unmasks increased EC apoptosis (Teichert-Kuliszewska 
et al., 2006). Moreover, we were able to establish that apop-
tosis was an important mechanism in the exaggerated PAH 
seen in Tie2-deficient animals in response to serotonergic 
stress, because this could be abrogated with the pan-caspase 
inhibitor Z-VAD. This is consistent with EC apoptosis play-
ing a central role in the pathogenesis of PAH, possibly by 
chronic hypoxia did not result in greater PAH in BMPR2+/ 
compared with WT mice (Long et al., 2006).
Lung Ang1 protein levels were reduced by treatment 
with serotonergic or inflammatory mediators in both WT 
and Tie2+/ mice. This was associated with decreased Tie2 
activation that was more pronounced in Tie2+/ compared 
with WT mice. Moreover, evidence of apoptosis was seen 
in the peripheral lungs in Tie2+/ mice exposed to 5-HT 
or IL-6 but not in WT littermates. Because Ang1 is primar-
ily produced by periendothelial support cells, we examined 
the effect of these agents on Ang1 secretion by cultured 
pulmonary artery SMCs. In parallel to our findings in vivo, 
we observed a dose-dependent reduction in Ang1 secre-
tion in response to both 5-HT and IL-6. Thus, in a Tie2-
deficient genetic background, these mediators could act to 
interfere with an important compensatory mechanism and 
exacerbate the effect of haploinsufficiency on the activity 
of the Tie2 pathway.
5-HT and IL-6 may also exert direct effects on EC in-
flammation and survival. Both IL-6 and 5-HT are known 
to be elevated in the serum of patients with PAH (Hervé   
et al., 1995; Humbert et al., 1995; Itoh et al., 2006), and 
they have been shown to induce PAH in rats and mice   
(Eddahibi et al., 1997; Golembeski et al., 2005; Steiner et al., 
2009). Increased circulating IL-6 has also been shown to be 
associated with increased evidence of EC apoptosis (Chirinos 
et al., 2005). As well, this mediator has been strongly impli-
cated in EC activation and proinflammatory signaling in the 
context of PAH (Yoshio et al., 1997; Lesprit et al., 1998; 
Nishimaki et al., 1999). Recently, it has been suggested that 
increased susceptibility to PAH induced by BMPR2 muta-
tions may be attributable in part to the loss of inhibitory ef-
fects of BMPs on IL-6 (Hagen et al., 2007), resulting in a 
positive feedback loop of inflammatory cytokine signaling. 
Figure 7.  Effect of 5-HT on pulmonary artery ECs deficient in Tie2 expression. (A) Decreased Tie2 protein expression in human pulmonary ar-
tery ECs subjected to Tie2-specific silencing siRNA compared with control (scrambled siRNA; n = 4 per group). (B) Percentage of cell death by annexin 
V/PI–based flow cytometry in human pulmonary artery ECs treated with control (scrambled) or Tie2 siRNA, and stimulated with 10 µM 5-HT for 24 h  
(n = 4 per group). Results in A and B are from four independent experiments. Data are presented as means ± SEM. *, P < 0.05; **, P < 0.01 as indicated.2230 TIE2 DEFICIENCY AND PULMONARY HYPERTENSION | Kugathasan et al.
Both agents decreased Ang1 secretion, which in the Tie2-
deficient background likely resulted in reduction in Tie2 ac-
tivity below a critical threshold. In contrast to some previous 
reports, overexpression of Ang1 had no deleterious effects 
on pulmonary hemodynamics or vascular remodeling, a find-
ing consistent with the now well-established role of Tie2   
activity in maintaining vascular homeostasis. Collectively, 
these findings suggest that rather than promoting vascular 
remodeling and PAH, pulmonary Ang1 may be protective 
by supporting the basal activation of endothelial Tie2. Thus, 
these data may have important clinical implications by sug-
gesting that therapeutic strategies based on inhibiting Tie2 
activity may be harmful, whereas Ang1 and other Tie2 ago-
nists may be useful in the treatment of this serious disorder.
MATERIALS AND METHODS
Animals
All animal procedures were approved by the Animal Care Committee of St. 
Michael’s Hospital. Breeding pairs to generate Tie2+/ mice and Ang1 BT 
mice were provided by D.J. Dumont (University of Toronto, Toronto, 
leading directly to the degeneration and loss of function of 
distal precapillary arterioles. More importantly, these findings 
also emphasize the protective role of the Tie2 signaling path-
way in preventing apoptosis and protecting against the devel-
opment of PAH. Thus, interventions that inhibit the apoptotic 
cascade may be therapeutically useful in preventing the pro-
gression of PAH and need to be investigated.
In this study, we have shown that Tie2 haploinsufficiency 
increased the susceptibility of transgenic mice to PAH, likely 
by sensitizing ECs to apoptosis in response to a second hit, 
such as exposure to 5-HT or a proinflammatory mediator.  Figure 9.  Effect of Ang1 overexpression on RVSP and RV hyper-
trophy. (A and B) No effect on RVSP (A; n = 6–10 mice per group) or RV 
hypertrophy (B; n = 6–10 mice per group) in NBT and Ang1 BT mice 
treated with 5 nmol/h 5-HT for 1 wk. Mice were released from doxycy-
cline suppression at 3 wk of age and exposed to 5-HT for 1 wk at 11–12 wk  
of age. Results are from three independent experiments. Data are pre-
sented as means ± SEM.
Figure 10.  Effect of Z-VAD on 5-HT–treated WT and Tie2+/ 
mice. (A) Significant decrease in RVSP in 5-HT–treated Tie2+/ mice 
after simultaneous treatment with 3 mg/kg Z-VAD for 1 wk (n = 3–5 
mice per group). (B) No significant change in RV hypertrophy was ob-
served (n = 3–5 mice per group). Results are from two independent ex-
periments. Data are presented as means ± SEM. **, P < 0.01 versus 5-HT +   
DMSO Tie2+/ mice.
Figure 8.  Effect of IL-6 on pulmonary arterial medial thickening. 
(A) Immunofluorescent images of vessels stained with –smooth muscle 
actin from 2 wk of (a) saline-treated WT, (b) saline-treated Tie2+/, (c) IL-6– 
treated WT, and (d) IL-6–treated Tie2+/ mice (n = 4 mice per group).  
(B) Increased percentage of wall thickness of pulmonary arteries <50 µm 
in external diameter in Tie2+/ mice exposed to IL-6 for 2 wk compared 
with WT mice and compared with saline-treated Tie2+/ mice (n = 4 mice 
per group). Results are from two independent experiments. Data are pre-
sented as means ± SEM. **, P < 0.01 as indicated. Bars, 25 µm.JEM VOL. 206, September 28, 2009 
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with a flushing buffer (10 mM sodium phosphate, 127 mM sodium chlo-
ride, 10 mM EDTA, 5 U/ml heparin). A 10% mixture of 0.2 µm of fluo-
rescent yellow-green microbeads (FluoSpheres; Invitrogen) reconstituted 
in low-temperature melting point agarose was injected into the pulmonary 
circulation via the RV. Crushed ice was then placed atop the mice to en-
hance gelling of the microbead–agarose mixture. After this, the lungs were 
inflated with cold 4% paraformaldehyde (PFA), and the heart–lung block 
was fixed in 4% PFA for 48 h and transferred to PBS for storage. The 
whole top right lobe was subjected to fluorescent microscopy (1× magni-
fication; Discovery V8 stereo microscope equipped with an AxioCam MR3   
camera) and images were acquired using AxioVision LE 4.6 software (all 
from Carl Zeiss, Inc.).
In vivo apoptosis analysis
This method was adapted from Cho et al. (1995). 5 µmol/kg PI (Sigma-Al-
drich) was injected via the right external jugular vein of anesthetized mice 
(200 mg/kg ketamine:10 mg/kg xylazine) and allowed to circulate for   
15 min before the mice were euthanized. The left atrium was transected, and 
the systemic and pulmonary circulations were flushed with PBS. Lungs were 
fixed in optimum cutting temperature and stored at 80°C overnight. The 
next day, 60-µm-thick cross sections of the left lobe of the lungs were cryo-
sectioned for confocal microscopy. Cells that did not exclude the PI were 
considered to be nonviable.
TUNEL
Apoptotic cells were detected in 5-µm-thick paraffin-embedded sections us-
ing a fluorescent TUNEL assay kit (Promega) according to manufacturer’s 
instructions. Nuclear counterstaining was performed using TO-PRO-3 
(1:2,500; Invitrogen), and sections were examined by confocal microscopy 
(40× magnification; Radiance 2100) and images were acquired using Laser-
Sharp software (both from Bio-Rad Laboratories). The number of TUNEL-
positive  nuclei  was  determined  by  examining  four  randomly  selected 
microscopic fields from each of four to five mice from each experimental group. 
The percentage of TUNEL positivity was calculated as follows: (number of 
TUNEL-positive nuclei)/(total number of nuclei) × 100%.
Western immunoblotting
Protein was extracted from the lungs of WT and Tie2+/ mice and subjected 
to immunoblotting. Membranes were incubated overnight at 4°C with rab-
bit eNOS antibody (1:1,000; Cell Signaling Technology), rabbit Phospho-
Tie2 antibody (1:1,000; Cell Signaling Technology), rabbit Tie2 antibody 
(1:1,000; Santa Cruz Biotechnology, Inc.), rabbit Ang1 antibody (1:1,000; 
Abcam), or goat Ang2 antibody (1:500; Santa Cruz Biotechnology, Inc.), 
and equivalent protein loading was demonstrated using mouse -actin anti-
body (1:5,000; Sigma-Aldrich).
Muscularization analysis
5-µm-thick paraffin-embedded sections were stained with a Cy3-conju-
gated monoclonal –smooth muscle actin antibody (1:200; Sigma-Aldrich), 
and nuclei were counterstained using TO-PRO-3 (1:2,500). Sections were 
examined by confocal microscopy (80× magnification; Radiance 2100) and 
images were acquired using LaserSharp software. The percentage of wall 
thickness was determined using the methodology by Beppu et al. (2004) 
and was as follows: % wall thickness = (WT1 + WT2)/(external diameter 
of vessel) × 100%, where WT1 and WT2 refer to wall thicknesses measured 
at two points diametrically opposite to each other. For each vessel, the per-
centage of wall thickness was calculated as the average determined from 
four regions of measurement.
Movat pentachrome staining
The Movat pentachrome staining was performed on 5-µm-thick paraffin-
embedded sections to demonstrate extracellular matrix components such 
as fibrin, collagen, elastin, and proteoglycans/glycosaminoglycans. Vessels 
from four to five randomly selected microscopic fields (10× magnification) 
from each of three mice from each experimental group were analyzed using 
Canada). WT littermates were used as controls in all experiments. Tie2+/ 
mice were generated by crossing Tie2+/ mice with WT mice. Ang1 trans-
genic mice were generated by breeding Enh-Tie2 tTA driver and pTET-
Ang1  responder  mice.  Ang1  overexpression  was  suppressed  throughout 
breeding by administering mice with drinking water containing 100 µg/ml 
doxycycline (Sigma-Aldrich). After weaning at 3 wk of age, mice were re-
leased from doxycycline, allowing for Ang1 overexpression. NBT littermate 
mice were used as controls. Offspring genotypes were determined via PCR 
(see Genotyping).
Genotyping
Genomic DNA was extracted from mouse ear-notch samples, and PCR was 
performed using the buffers and PCR reaction mix from the REDExtract-N- 
Amp tissue PCR kit (Sigma-Aldrich), according to the manufacturer’s 
instructions. A 0.5-µm mixture of the following primers was used in the 
PCR to detect the endogenous Tie2 (150 bp) and mutated Tie2 (450 bp):   
endogenous  forward,  5-AGCGCGTGGACCATGCGAGC-3;  endoge-
nous reverse, 5-CCATTGCTCAGCGGTGCTGTCCAT-3; and mutant 
forward, 5-AGGAGCAAGCTGACTCCACAG-3. The PCR thermal 
cycling parameters included an initial denaturation at 94°C for 3 min, fol-
lowed by 30 cycles consisting of denaturation at 95°C for 30 s, annealing at 
54°C for 40 s, and extension at 72°C for 30 s According to this, a final ex-
tension at 72°C for 10 min was performed, and the amplified DNA was re-
solved in a 1.5% agarose gel. Ang1 BT mice were identified via PCR using 
the following primer pairs to detect the tetracycline transactivator (tTA; 
500 bp) and the human Ang1 transgene (hAng1; 350 bp): tTA forward, 
5-CTCACTTTTGCCCTTTAGAA-3; tTA reverse, 5-GCTGTACGC-
GGACCCACTTT-3; hAng1 forward, 5-ATAGGAACCAGCCTCCTC-
TCT-3; and hAng1 reverse 5-AAGGACACTGTTGTTGGTGGTA-3.
Detecting plasma human Ang1 in Ang1 BT mice
Cardiac puncture was performed on anesthetized mice, and blood was col-
lected from both NBT and Ang1 BT mice. Plasma was isolated and stored at 
80°C.  Human  Ang1  expression  in  mouse  plasma  was  determined  by 
ELISA according to the manufacturer’s instructions (R&D Systems).
In vivo experiments
Hypoxia-induced  PAH.  Groups  of  three  mice  were  placed  in  sealed 
Plexiglas, normobaric chambers (12 × 5 × 7 in) for 1 wk. The O2 concentra-
tion in the chamber was maintained at 8–10% by controlling the inflow rates 
from tanks containing mixed air and nitrogen. The O2 concentration in the 
chamber was measured daily using an O2 analyzer (Engineered Systems and 
Designs). Control mice were maintained in room air.
5-HT–induced PAH. Tie2+/ and WT littermate mice as well as Ang1 BT 
and NBT littermate mice (11–12 wk old) received 5 nmol/h of 5-HT (Sigma-
Aldrich) or saline (control) via s.c. placed osmotic mini pumps (Alzet Osmotic 
Pumps) over a 1-wk duration. In separate experiments, mice receiving either 
saline or 5-HT also received daily i.p. injection of 3 mg/kg of the pan-caspase 
inhibitor Z-VAD-FMK (R&D Systems) or DMSO (control) for 1 wk.
IL-6–induced PAH. WT littermates and Tie2+/ mice received s.c. injec-
tions of 200 ng/kg/d of recombinant mouse IL-6 (Sigma-Aldrich) or saline 
(control) over a 1- or 2-wk duration.
Hemodynamic evaluation
Systemic SBP was determined by inserting a 1.4F Millar catheter (Millar 
Instruments, Inc.) into the left ventricle of anesthetized mice (200 mg/kg 
ketamine:10 mg/kg xylazine i.p.). Similarly, RVSP was determined in 
anesthetized mice by inserting the 1.4F Millar catheter into the RV. RV hy-
pertrophy was assessed by evaluating the mass ratio of the RV to the left 
ventricle plus septum.
Fluorescent microangiography
This technique was adapted from Dutly et al. (2006). In brief, mice were 
anaesthetized and the pulmonary vessels were flushed through the RV 2232 TIE2 DEFICIENCY AND PULMONARY HYPERTENSION | Kugathasan et al.
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a bright-field upright light microscope (model E800) equipped with a digi-
tal camera (DXM 1200), and images were acquired using Act-1 software 
(all from Nikon).
Human pulmonary artery SMC culture
Human pulmonary artery SMCs (Lonza, Ltd.) at 70–80% confluency were 
serum starved in basal medium with 0.1% BSA for 24 h and exposed to   
5-HT (Sigma-Aldrich) at concentrations of 108–105 M for 24 h. In a sepa-
rate  experiment,  serum-starved  cells  were  exposed  to  a  combination  of 
human IL-6 and human sIL-6R (IL-6 + sIL-6R; Sigma-Aldrich), each at 
concentrations of 10, 50, and 100 ng/ml for 24 h. At the end of the experi-
ments, supernatants were collected for ELISA and cells were harvested for 
protein quantification.
Detecting membrane-bound IL-6R
Protein was harvested from human pulmonary artery SMCs and human en-
dothelial progenitor cells were cultured for 7 d (positive control). Mem-
branes were incubated overnight at 4°C with rabbit IL-6R antibody (1:500; 
Santa Cruz Biotechnology, Inc.).
ELISA
Human Ang1 levels from human pulmonary artery SMC supernatants were 
measured according to the manufacturer’s instructions (R&D Systems).
Human pulmonary artery EC Tie2 siRNA
siRNA-mediated inhibition of Tie2 gene expression (Santa Cruz Biotech-
nology, Inc.) in human pulmonary artery ECs (Lonza, Ltd.) was performed 
according to the manufacturer’s instructions, and control cells were sub-
jected to scrambled siRNA transfection. After siRNA treatment, cells were 
exposed to 105 M 5-HT in basal medium with 0.2% FBS for 24 h. At the 
end of this treatment, cells were labeled with annexin V and PI (Annexin-V-
FLUOS staining kit; Roche) and analyzed by flow cytometry to determine 
the percentage of cell death.
Statistical analysis
All data are presented as means ± SEM. For in vivo experiments, means of 
two groups were compared using either an unpaired t test, or when appro-
priate, the nonparametric Mann-Whitney U test. Differences among multi-
ple means were determined by analysis of variance (ANOVA), followed by 
the Student-Newman-Keuls post-hoc analysis, or the nonparametric Kruskal-
Wallis test followed by the Dunn’s post-hoc analysis. For in vitro experi-
ments, repeated-measures ANOVA was used when appropriate, followed by 
the Dunnett’s post-hoc analysis.
Online supplemental material
Fig. S1 demonstrates that hypoxia did not elicit more significant PAH in 
Tie2+/ compared with WT mice. Fig. S2 confirms that the membrane-
bound  IL-6R  is  not  expressed  in  pulmonary  arterial  SMCs  in  culture.   
Fig. S3 demonstrates that lung eNOS protein levels are not significantly 
altered in WT or Tie2+/ mice after exposure to 5-HT, although a trend 
toward a decrease in eNOS protein levels was present in the Tie2+/ 
mice. Fig. S4 illustrates the presence of nonviable cells in the lungs of   
5-HT–treated Tie2+/ mice via in vivo PI uptake. Fig. S5 demonstrates 
the absence of any overt phenotypic differences after Movat pentachrome 
staining between WT and Tie2+/ mice treated with 5-HT or IL-6. Fig. S6 
confirms the expression of human Ang1 protein in the plasma of Ang1 
BT  mice.  Online  supplemental  material  is  available  at  http://www.jem 
.org/cgi/content/full/jem.20090389/DC1.
We thank Ms. C. Wang, Mr. M. Robb, Dr. M. Golam Kabir, and Dr. R.N.N. Han for 
technical assistance, and Ms. L. Morikawa for the Movat pentachrome staining. 
We also thank Mr. P.F.H. Lai, Dr. M.E. Ward, and Dr. K. Teichert-Kuliszewska for 
helpful discussions.
This work was supported by grants to D.J. Stewart from the Canadian 
Institutes of Health Research (MOP-57726 and MOP-82791), and L. Kugathasan JEM VOL. 206, September 28, 2009 
ARTICLE
2233
Lai, D.M., H. Li, C.C. Lee, Y.S. Tzeng, Y.H. Hsieh, W.M. Hsu, F.J. Hsieh, 
J.T. Cheng, and Y.K. Tu. 2008. Angiopoietin-like protein 1 decreases 
blood brain barrier damage and edema following focal cerebral ischemia in 
mice. Neurochem. Int. 52:470–477. doi:10.1016/j.neuint.2007.08.010
Lee, S.L., W.W. Wang, J.J. Lanzillo, and B.L. Fanburg. 1994. Serotonin 
produces both hyperplasia and hypertrophy of bovine pulmonary artery 
smooth muscle cells in culture. Am. J. Physiol. 266:L46–L52.
Lee, J.S., S.H. Song, J.M. Kim, I.S. Shin, K.L. Kim, Y.L. Suh, H.Z. Kim, 
G.Y. Koh, J. Byun, E.S. Jeon, et al. 2008. Angiopoietin-1 prevents hyper-
tension and target organ damage through its interaction with endothelial 
Tie2 receptor. Cardiovasc. Res. 78:572–580. doi:10.1093/cvr/cvn048
Lesprit, P., B. Godeau, F.J. Authier, M. Soubrier, M. Zuber, C. Larroche, 
J.P. Viard, B. Wechsler, and R. Gherardi. 1998. Pulmonary hyperten-
sion in POEMS syndrome: a new feature mediated by cytokines. Am. 
J. Respir. Crit. Care Med. 157:907–911.
Long,  L.,  M.R.  MacLean,  T.K.  Jeffery,  I.  Morecroft,  X.  Yang,  N. 
Rudarakanchana,  M.  Southwood,  V.  James,  R.C.  Trembath,  and 
N.W. Morrell. 2006. Serotonin increases susceptibility to pulmonary   
hypertension  in  BMPR2-deficient  mice.  Circ.  Res.  98:818–827. 
doi:10.1161/01.RES.0000215809.47923.fd
MacLean, M.R., G. Sweeney, M. Baird, K.M. McCulloch, M. Houslay, 
and I. Morecroft. 1996. 5-Hydroxytryptamine receptors mediating va-
soconstriction in pulmonary arteries from control and pulmonary hy-
pertensive rats. Br. J. Pharmacol. 119:917–930.
MacLean, M.R., G.A. Deuchar, M.N. Hicks, I. Morecroft, S. Shen, J. 
Sheward,  J.  Colston,  L.  Loughlin,  M.  Nilsen,  Y.  Dempsie,  and  A. 
Harmar. 2004. Overexpression of the 5-hydroxytryptamine transporter 
gene: effect on pulmonary hemodynamics and hypoxia-induced pul-
monary  hypertension.  Circulation.  109:2150–2155.  doi:10.1161/01.
CIR.0000127375.56172.92
Maisonpierre,  P.C.,  C.  Suri,  P.F.  Jones,  S.  Bartunkova,  S.J.  Wiegand, 
C.  Radziejewski,  D.  Compton,  J.  McClain,  T.H.  Aldrich,  N. 
Papadopoulos,  et  al.  1997.  Angiopoietin-2,  a  natural  antago-
nist  for  Tie2  that  disrupts  in  vivo  angiogenesis.  Science.  277:55–60. 
doi:10.1126/science.277.5322.55
Marcos, E., S. Adnot, M.H. Pham, A. Nosjean, B. Raffestin, M. Hamon, 
and S. Eddahibi. 2003. Serotonin transporter inhibitors protect against 
hypoxic  pulmonary  hypertension.  Am.  J.  Respir.  Crit.  Care  Med. 
168:487–493. doi:10.1164/rccm.200210-1212OC
Modur, V., Y. Li, G.A. Zimmerman, S.M. Prescott, and T.M. McIntyre. 
1997.  Retrograde  inflammatory  signaling  from  neutrophils  to  en-
dothelial cells by soluble interleukin-6 receptor alpha. J. Clin. Invest. 
100:2752–2756. doi:10.1172/JCI119821
Morecroft, I., R.P. Heeley, H.M. Prentice, A. Kirk, and M.R. MacLean. 
1999. 5-hydroxytryptamine receptors mediating contraction in human 
small muscular pulmonary arteries: importance of the 5-HT1B receptor. 
Br. J. Pharmacol. 128:730–734. doi:10.1038/sj.bjp.0702841
Morecroft, I., Y. Dempsie, M. Bader, D.J. Walther, K. Kotnik, L. Loughlin, 
M.  Nilsen,  and  M.R.  MacLean.  2007.  Effect  of  tryptophan  hy-
droxylase 1 deficiency on the development of hypoxia-induced pul-
monary  hypertension.  Hypertension.  49:232–236.  doi:10.1161/01.
HYP.0000252210.58849.78
Newman, J.H., R.C. Trembath, J.A. Morse, E. Grunig, J.E. Loyd, S. Adnot, 
F. Coccolo, C. Ventura, J.A. Phillips III, J.A. Knowles, et al. 2004. 
Genetic basis of pulmonary arterial hypertension: current understanding 
and future directions. J. Am. Coll. Cardiol. 43(12 Suppl. S):33S–39S. 
doi:10.1016/j.jacc.2004.02.028
Nishimaki, T., S. Aotsuka, H. Kondo, K. Yamamoto, Y. Takasaki, M. 
Sumiya, and R. Yokohari. 1999. Immunological analysis of pulmonary 
hypertension in connective tissue diseases. J. Rheumatol. 26:2357–2362.
Papapetropoulos, A., D. Fulton, K. Mahboubi, R.G. Kalb, D.S. O’Connor, 
F. Li, D.C. Altieri, and W.C. Sessa. 2000. Angiopoietin-1 inhibits en-
dothelial cell apoptosis via the Akt/survivin pathway. J. Biol. Chem. 
275:9102–9105. doi:10.1074/jbc.275.13.9102
Robbins, I.M., E.V. Colvin, T.P. Doyle, W.E. Kemp, J.E. Loyd, W.S. 
McMahon, and G.N. Kay. 1998. Pulmonary vein stenosis after catheter 
ablation of atrial fibrillation. Circulation. 98:1769–1775.
Rothman,  R.B.,  M.A.  Ayestas,  C.M.  Dersch,  and  M.H.  Baumann.  1999. 
Aminorex, fenfluramine, and chlorphentermine are serotonin transporter 
Dutly, A.E., L. Kugathasan, J.E. Trogadis, S.H. Keshavjee, D.J. Stewart, 
and D.W. Courtman. 2006. Fluorescent microangiography (FMA): an 
improved tool to visualize the pulmonary microvasculature. Lab. Invest. 
86:409–416. doi:10.1038/labinvest.3700399
Eddahibi, S., B. Raffestin, I. Pham, J.M. Launay, P. Aegerter, M. Sitbon, 
and S. Adnot. 1997. Treatment with 5-HT potentiates development 
of pulmonary hypertension in chronically hypoxic rats. Am. J. Physiol. 
272:H1173–H1181.
Eddahibi,  S.,  N.  Hanoun,  L.  Lanfumey,  K.P.  Lesch,  B.  Raffestin,  M. 
Hamon, and S. Adnot. 2000. Attenuated hypoxic pulmonary hyperten-
sion in mice lacking the 5-hydroxytryptamine transporter gene. J. Clin. 
Invest. 105:1555–1562. doi:10.1172/JCI8678
Eddahibi,  S.,  C.  Guignabert,  A.M.  Barlier-Mur,  L.  Dewachter,  E. 
Fadel,  P.  Dartevelle,  M.  Humbert,  G.  Simonneau,  N.  Hanoun, 
F.  Saurini,  et  al.  2006.  Cross  talk  between  endothelial  and  smooth 
muscle  cells  in  pulmonary  hypertension:  critical  role  for  serotonin-
induced  smooth  muscle  hyperplasia.  Circulation.  113:1857–1864. 
doi:10.1161/CIRCULATIONAHA.105.591321
Golembeski, S.M., J. West, Y. Tada, and K.A. Fagan. 2005. Interleukin-
6 causes mild pulmonary hypertension and augments hypoxia-induced 
pulmonary  hypertension  in  mice.  Chest.  128(6  Suppl.):572S–573S. 
doi:10.1378/chest.128.6_suppl.572S-a
Guignabert, C., B. Raffestin, R. Benferhat, W. Raoul, P. Zadigue, D. 
Rideau,  M.  Hamon,  S.  Adnot,  and  S.  Eddahibi.  2005.  Serotonin 
transporter  inhibition  prevents  and  reverses  monocrotaline-in-
duced  pulmonary  hypertension  in  rats.  Circulation.  111:2812–2819. 
doi:10.1161/CIRCULATIONAHA.104.524926
Hagen, M., K. Fagan, W. Steudel, M. Carr, K. Lane, D.M. Rodman, and J. 
West. 2007. Interaction of interleukin-6 and the BMP pathway in pulmo-
nary smooth muscle. Am. J. Physiol. Lung Cell. Mol. Physiol. 292:L1473–
L1479. doi:10.1152/ajplung.00197.2006
Hervé, P., J.M. Launay, M.L. Scrobohaci, F. Brenot, G. Simonneau, P. 
Petitpretz, P. Poubeau, J. Cerrina, P. Duroux, and L. Drouet. 1995. 
Increased plasma serotonin in primary pulmonary hypertension. Am.   
J. Med. 99:249–254. doi:10.1016/S0002-9343(99)80156-9
Hironaka, E., M. Hongo, A. Sakai, E. Mawatari, F. Terasawa, N. Okumura, 
A. Yamazaki, Y. Ushiyama, Y. Yazaki, and O. Kinoshita. 2003. Serotonin 
receptor antagonist inhibits monocrotaline-induced pulmonary hy-
pertension and prolongs survival in rats. Cardiovasc. Res. 60:692–699.   
doi:10.1016/j.cardiores.2003.09.023
Humbert, M., G. Monti, F. Brenot, O. Sitbon, A. Portier, L. Grangeot-Keros, 
P. Duroux, P. Galanaud, G. Simonneau, and D. Emilie. 1995. Increased 
interleukin-1 and interleukin-6 serum concentrations in severe primary 
pulmonary hypertension. Am. J. Respir. Crit. Care Med. 151:1628–1631.
Itoh, T., N. Nagaya, H. Ishibashi-Ueda, S. Kyotani, H. Oya, F. Sakamaki, 
H. Kimura, and N. Nakanishi. 2006. Increased plasma monocyte che-
moattractant protein-1 level in idiopathic pulmonary arterial hyperten-
sion. Respirology. 11:158–163. doi:10.1111/j.1440-1843.2006.00821.x
Janssens, S.P., K.D. Bloch, Z. Nong, R.D. Gerard, P. Zoldhelyi, and D. 
Collen. 1996. Adenoviral-mediated transfer of the human endothelial 
nitric oxide synthase gene reduces acute hypoxic pulmonary vasocon-
striction in rats. J. Clin. Invest. 98:317–324. doi:10.1172/JCI118795
Keegan, A., I. Morecroft, D. Smillie, M.N. Hicks, and M.R. MacLean. 
2001. Contribution of the 5-HT(1B) receptor to hypoxia-induced pul-
monary hypertension: converging evidence using 5-HT(1B)-receptor 
knockout mice and the 5-HT(1B/1D)-receptor antagonist GR127935. 
Circ. Res. 89:1231–1239. doi:10.1161/hh2401.100426
Kido, M., L. Du, C.C. Sullivan, R. Deutsch, S.W. Jamieson, and P.A. 
Thistlethwaite. 2005. Gene transfer of a TIE2 receptor antagonist pre-
vents pulmonary hypertension in rodents. J. Thorac. Cardiovasc. Surg. 
129:268–276. doi:10.1016/j.jtcvs.2004.09.013
Kim, I., J.H. Kim, S.O. Moon, H.J. Kwak, N.G. Kim, and G.Y. Koh. 2000. 
Angiopoietin-2 at high concentration can enhance endothelial cell sur-
vival through the phosphatidylinositol 3-kinase/Akt signal transduction 
pathway. Oncogene. 19:4549–4552. doi:10.1038/sj.onc.1203800
Kugathasan, L., A.E. Dutly, Y.D. Zhao, Y. Deng, M.J. Robb, S. Keshavjee, 
and D.J. Stewart. 2005. Role of angiopoietin-1 in experimental and 
human pulmonary arterial hypertension. Chest. 128(6 Suppl.):633S–642S. 
doi:10.1378/chest.128.6_suppl.633S2234 TIE2 DEFICIENCY AND PULMONARY HYPERTENSION | Kugathasan et al.
substrates. Implications for primary pulmonary hypertension. Circulation. 
100:869–875.
Sato, T.N., Y. Tozawa, U. Deutsch, K. Wolburg-Buchholz, Y. Fujiwara, 
M. Gendron-Maguire, T. Gridley, H. Wolburg, W. Risau, and Y. Qin. 
1995. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in 
blood vessel formation. Nature. 376:70–74. doi:10.1038/376070a0
Song,  Y.,  J.E.  Jones,  H.  Beppu,  J.F.  Keaney  Jr.,  J.  Loscalzo,  and  Y.Y. 
Zhang.  2005.  Increased  susceptibility  to  pulmonary  hypertension 
in  heterozygous  BMPR2-mutant  mice.  Circulation.  112:553–562. 
doi:10.1161/CIRCULATIONAHA.104.492488
Song, Y., L. Coleman, J. Shi, H. Beppu, K. Sato, K. Walsh, J. Loscalzo, 
and  Y.Y.  Zhang.  2008.  Inflammation,  endothelial  injury,  and  per-
sistent  pulmonary  hypertension  in  heterozygous  BMPR2-mu-
tant  mice.  Am.  J.  Physiol.  Heart  Circ.  Physiol.  295:H677–H690. 
doi:10.1152/ajpheart.91519.2007
Steiner, M.K., O.L. Syrkina, N. Kolliputi, E.J. Mark, C.A. Hales, and A.B. 
Waxman. 2009. Interleukin-6 overexpression induces pulmonary hy-
pertension. Circ. Res. 104:236–244.
Sullivan,  C.C.,  L.  Du,  D.  Chu,  A.J.  Cho,  M.  Kido,  P.L.  Wolf,  S.W. 
Jamieson, and P.A. Thistlethwaite. 2003. Induction of pulmonary hy-
pertension by an angiopoietin 1/TIE2/serotonin pathway. Proc. Natl. 
Acad. Sci. USA. 100:12331–12336. doi:10.1073/pnas.1933740100
Suri, C., P.F. Jones, S. Patan, S. Bartunkova, P.C. Maisonpierre, S. Davis, 
T.N. Sato, and G.D. Yancopoulos. 1996. Requisite role of angiopoi-
etin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. 
Cell. 87:1171–1180. doi:10.1016/S0092-8674(00)81813-9
Taraseviciene-Stewart, L., Y. Kasahara, L. Alger, P. Hirth, G. Mc Mahon, J. 
Waltenberger, N.F. Voelkel, and R.M. Tuder. 2001. Inhibition of the 
VEGF receptor 2 combined with chronic hypoxia causes cell death-de-
pendent pulmonary endothelial cell proliferation and severe pulmonary 
hypertension. FASEB J. 15:427–438. doi:10.1096/fj.00-0343com
Teichert-Kuliszewska, K., P.C. Maisonpierre, N. Jones, A.I. Campbell, Z. 
Master, M.P. Bendeck, K. Alitalo, D.J. Dumont, G.D. Yancopoulos, 
and D.J. Stewart. 2001. Biological action of angiopoietin-2 in a fibrin 
matrix  model  of  angiogenesis  is  associated  with  activation  of  Tie2. 
Cardiovasc. Res. 49:659–670. doi:10.1016/S0008-6363(00)00231-5
Teichert-Kuliszewska,  K.,  M.J.  Kutryk,  M.A.  Kuliszewski,  G.  Karoubi, 
D.W. Courtman, L. Zucco, J. Granton, and D.J. Stewart. 2006. Bone 
morphogenetic protein receptor-2 signaling promotes pulmonary arte-
rial endothelial cell survival: implications for loss-of-function mutations 
in the pathogenesis of pulmonary hypertension. Circ. Res. 98:209–217. 
doi:10.1161/01.RES.0000200180.01710.e6
Thistlethwaite, P.A., S.H. Lee, L.L. Du, P.L. Wolf, C. Sullivan, S. Pradhan, 
R. Deutsch, and S.W. Jamieson. 2001. Human angiopoietin gene ex-
pression is a marker for severity of pulmonary hypertension in patients 
undergoing pulmonary thromboendarterectomy. J. Thorac. Cardiovasc. 
Surg. 122:65–73. doi:10.1067/mtc.2001.113753
Tsao, H.M., and S.A. Chen. 2002. Evaluation of pulmonary vein steno-
sis after catheter ablation of atrial fibrillation. Card. Electrophysiol. Rev. 
6:397–400. doi:10.1023/A:1021132307986
Tuder,  R.M.,  C.D.  Cool,  M.  Yeager,  L.  Taraseviciene-Stewart, 
T.M.  Bull,  and  N.F.  Voelkel.  2001.  The  pathobiology  of  pulmo-
nary  hypertension.  Endothelium.  Clin.  Chest  Med.  22:405–418. 
doi:10.1016/S0272-5231(05)70280-X
Vikkula, M., L.M. Boon, K.L. Carraway III, J.T. Calvert, A.J. Diamonti, 
B.  Goumnerov,  K.A.  Pasyk,  D.A.  Marchuk,  M.L.  Warman,  L.C. 
Cantley, et al. 1996. Vascular dysmorphogenesis caused by an activat-
ing mutation in the receptor tyrosine kinase TIE2. Cell. 87:1181–1190. 
doi:10.1016/S0092-8674(00)81814-0
Voelkel, N.F., and C. Cool. 2004. Pathology of pulmonary hypertension. 
Cardiol. Clin. 22:343–351. doi:10.1016/j.ccl.2004.04.010
Ward, N.L., and D.J. Dumont. 2002. The angiopoietins and Tie2/Tek: 
adding to the complexity of cardiovascular development. Semin. Cell 
Dev. Biol. 13:19–27. doi:10.1006/scdb.2001.0288
West, J., J. Harral, K. Lane, Y. Deng, B. Ickes, D. Crona, S. Albu, D. Stewart, 
and  K.  Fagan.  2008.  Mice  expressing  BMPR2R899X  transgene  in 
smooth muscle develop pulmonary vascular lesions. Am. J. Physiol. Lung 
Cell. Mol. Physiol. 295:L744–L755. doi:10.1152/ajplung.90255.2008
Witzenbichler, B., P.C. Maisonpierre, P. Jones, G.D. Yancopoulos, and 
J.M. Isner. 1998. Chemotactic properties of angiopoietin-1 and -2, li-
gands for the endothelial-specific receptor tyrosine kinase Tie2. J. Biol. 
Chem. 273:18514–18521. doi:10.1074/jbc.273.29.18514
Wong, A.L., Z.A. Haroon, S. Werner, M.W. Dewhirst, C.S. Greenberg, 
and K.G. Peters. 1997. Tie2 expression and phosphorylation in angio-
genic and quiescent adult tissues. Circ. Res. 81:567–574.
Yang, H.M., C.K. Lai, J. Patel, J. Moore, P.S. Chen, K. Shivkumar, 
and  M.C.  Fishbein.  2007.  Irreversible  intrapulmonary  vascu-
lar  changes  after  pulmonary  vein  stenosis  complicating  cath-
eter  ablation  for  atrial  fibrillation.  Cardiovasc.  Pathol.  16:51–55. 
doi:10.1016/j.carpath.2006.07.007
Yoshio, T., J.I. Masuyama, N. Kohda, D. Hirata, H. Sato, M. Iwamoto, 
A. Mimori, A. Takeda, S. Minota, and S. Kano. 1997. Association of 
interleukin 6 release from endothelial cells and pulmonary hypertension 
in SLE. J. Rheumatol. 24:489–495.
Zhao,  Y.D.,  A.I.  Campbell,  M.  Robb,  D.  Ng,  and  D.J.  Stewart. 
2003.  Protective  role  of  angiopoietin-1  in  experimental  pul-
monary  hypertension.  Circ.  Res.  92:984–991.  doi:10.1161/01.
RES.0000070587.79937.F0
Zhao, Y.D., D.W. Courtman, Y. Deng, L. Kugathasan, Q. Zhang, and 
D.J.  Stewart.  2005.  Rescue  of  monocrotaline-induced  pulmonary 
arterial hypertension using bone marrow-derived endothelial-like 
progenitor cells: efficacy of combined cell and eNOS gene ther-
apy  in  established  disease.  Circ.  Res.  96:442–450.  doi:10.1161/01.
RES.0000157672.70560.7b